Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Individuals with one of the following histologically confirmed tumors:~  * stage IIIB/IV non-small-cell lung cancer~ * metastatic breast cancer~ * androgen insensitive prostate cancer and are scheduled to receive at least 4 weeks of chemotherapy, including a taxane.~* Has progression or relapse after treatment with at least one regimen of chemotherapy or hormone therapy.~* Has a hemoglobin value of greater than or equal to 8 and less than 10.5 g/dL within 1 week prior to administration of study drug.~* Has an Eastern Cooperative Oncology Group Performance Status of 0-2.~* Has one ferritin level greater than or equal to 100 ng/mL within 4 weeks prior to study drug administration.~* Has one serum or red cell folate level above the lower limit of normal within 4 weeks prior to study drug administration.~* Has one vitamin B12 level above the lower limit of normal within 4 weeks prior to study drug administration.~* Has one absolute neutrophil count greater than or equal to 1.5 x 109/L within 1 week prior to administration of study drug.~* The subject has a serum creatinine less than or equal to 1.5 mg/dL or a measured creatinine clearance greater than 60 mL/min.~* The subject has one platelet count greater than or equal to 100 x 109/L within 1 week prior to administration of study drug.~* The subject has a Life expectancy greater than 4 months.~* The subject has a body mass index between 18 and 30 kg/m2, inclusive, prior to study drug administration.~* The subject has a negative test result for hepatitis B surface antigen, and hepatitis C virus antibody at Screening.~Exclusion Criteria:~* Has a history of failure to respond to erythropoiesis-stimulating agent treatment.~* Has had treatment with any erythropoiesis-stimulating agent in the past 4 weeks.~* Is known to have antibodies to other erythropoiesis-stimulating agents or history of Pure Red Cell Aplasia.~* Has received Peginesatide in a previous clinical study or as a therapeutic agent.~* Has a history of hypersensitivity or allergies to Peginesatide, other erythropoiesis-stimulating agents or related compounds.~* Has had red blood cell transfusion within 4 weeks prior to study drug administration.~* Has known hemoglobinopathy (eg, homozygous sickle-cell disease, thalassemia of all types, etc).~* Has known hemolytic condition.~* Has known blood loss as a cause of anemia, iron deficiency anemia, or anemia caused by gastrointestinal bleeding.~* Has any previous or planned radiotherapy to more than 30% of active bone marrow.~* Has donated more than 400 mL of blood within the 90 days preceding the beginning of the study.~* Has known intolerance to parenteral iron supplementation.~* Has received IV iron within 1 week of study drug administration.~* Has history of bone marrow or peripheral blood cell transplantation.~* Has central nervous system metastases.~* Has a history of deep venous thrombosis, pulmonary embolism or other thrombotic event (eg, stroke, myocardial infarction, etc.) in the previous 6 months or known history of hypercoagulable disorder.~* Has uncontrolled, or symptomatic inflammatory disease (eg, rheumatoid arthritis, systemic lupus erythematosus, etc).~* Has poorly controlled hypertension per the investigator's judgment within 4 weeks prior to study drug administration (eg, systolic greater than or equal to 170 mm Hg or diastolic greater than or equal to 100 mm Hg on repeat readings).~* Has had a seizure in the 6 months prior to study drug administration.~* Has advanced chronic congestive heart failure - New York Heart Association Class III or IV.~* Has a history or presence of an abnormal electrocardiogram at Screening that, in the investigator's opinion, is clinically significant.~* Has a known history of human immunodeficiency virus.~* Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as consumption of more than 4 alcoholic drinks per day) within 1 year prior to Baseline.~* Has aspartate aminotransferase or alanine aminotransferase greater than 2.5 times the upper limit of normal (aspartate aminotransferase or alanine aminotransferase greater than 5 times the upper limit of normal if liver metastases are present), active liver disease or jaundice.~* Is currently taking or anticipated to require anticoagulants other than aspirin (eg, coumadin, ticlopidine, etc.).~* Has a bilirubin greater than the upper limit of normal.~* Has pyrexia/fever greater than or equal to 39°C within 48 hours prior to study drug administration.~* Has high likelihood of early withdrawal or interruption of the study (eg, myocardial infarction within the past 3 months, severe or unstable coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric or neurological abnormalities, or any other clinically significant medical diseases or conditions within the prior 6 months that may, in the investigator's opinion, interfere with assessment or follow-up of the subject).~* Has anticipated elective surgery during the study period.~* Has exposure to any investigational agent within 1 month prior to administration of study drug or planned receipt during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval